TerminatedPhase 1

Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

Stopped: Requested by PI during yearly Continuing Review

United States30 participantsStarted 2010-07-16

Plain-language summary

The goal of this clinical research study is to study the safety of giving larger daily doses of proton radiation therapy than the standard dose levels given to treat lung cancer. Researchers want to find the highest daily dose of proton radiation that can be given without having to stop therapy due to side effects.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically or cytologically documented NSCLC, SCLC, thymic tumors, or carcinoid tumors
✓. Patients not receiving concurrent chemotherapy
✓. Patients that are eligible for concurrent treatment with biologic agents (epidermal growth factor receptor \[EGFR\] or vascular endothelial growth factor \[VEGF\] inhibitors) will be eligible for the study.

Exclusion criteria

✕. Prior radiotherapy to the chest
✕. Life expectancy \<6 months
✕. Pregnancy

What they're measuring

Maximum Tolerated Dose (MTD) of Hypofractionated Proton Therapy

Timeframe: 1 month after completion of radiation therapy

Trial details

NCT IDNCT01165658

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-07-19

View on ClinicalTrials.gov More Non-small Cell Lung Cancer trials